Assessment of the U.S. Food and Drug Administration's risk evaluation and mitigation strategy (REMS) for prasugrel (EFFIENT): A narrative review

Background: Prasugrel, first approved in 2009, was subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to mitigate the risk of bleeding associated with its use. Methods: We performed a narrative review of FDA documents obtained through a Freedom of Infor...

Full description

Bibliographic Details

Published in:	American Heart Journal Plus
Main Authors:	Thomas Metkus, Jill Curran, Shanshan Lin, Dima M. Qato, G. Caleb Alexander
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Subjects:	U.S. Food and Drug Administration Risk evaluation and mitigation programs Drug risks
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666602224000028